MitoDys Therapeutics Ltd is a start-up 'virtual' company that aims to discover and develop highly innovative therapeutic agents targeted to both the motor and non-motor symptoms prevalent in patients with select rare neurodegenerative conditions.  It uses the tools of Network Pharmacology to analyse the interplay between dysfunctional cascading and cooperative cellular and inflammatory functions, to uncover multi-interventional pharmacological agents aimed at alleviating symptoms while modifying the course of the disease.

The company is based around Oxford in the UK and has assembled both an experienced management team and world class group of scientific and clinical advisors to carry its drug discovery and development programs forward. It is targeting two important indications in Parkinson's patients: disease modification and non-motor symptoms in early stage patients and the delay or prevention of the onset of dyskinesia in later stage patients.